Deltec Asset Management LLC Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Deltec Asset Management LLC purchased a new position in Revance Therapeutics, Inc. (NASDAQ:RVNC) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 100,000 shares of the biopharmaceutical company’s stock, valued at approximately $304,000. Deltec Asset Management LLC owned 0.10% of Revance Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of RVNC. LMR Partners LLP acquired a new stake in shares of Revance Therapeutics in the 3rd quarter valued at $11,648,000. Alpine Associates Management Inc. bought a new stake in shares of Revance Therapeutics during the 3rd quarter worth $21,605,000. Oddo BHF Asset Management Sas acquired a new stake in Revance Therapeutics in the third quarter valued at about $3,763,000. FNY Investment Advisers LLC grew its position in Revance Therapeutics by 160.4% in the fourth quarter. FNY Investment Advisers LLC now owns 477,823 shares of the biopharmaceutical company’s stock valued at $1,452,000 after acquiring an additional 294,323 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in Revance Therapeutics during the third quarter worth about $2,315,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Price Performance

NASDAQ:RVNC opened at $3.64 on Wednesday. Revance Therapeutics, Inc. has a 52 week low of $2.30 and a 52 week high of $7.56. The firm’s fifty day moving average is $3.40 and its 200-day moving average is $4.59.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. On average, research analysts forecast that Revance Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Barclays decreased their price target on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd. Mizuho dropped their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday, December 10th. HC Wainwright restated a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a research report on Friday, November 8th. StockNews.com initiated coverage on Revance Therapeutics in a research report on Wednesday, January 29th. They issued a “hold” rating for the company. Finally, Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $8.39.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.